Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting

Fig. 2

IGFBP-3 impairs C2C12 myoblast proliferation and C2C12 myotube differentiation. a-b C2C12 myoblasts were seeded at density of 20,000 cells/well and cultured in growth medium with or without different doses of IGFBP-3 for 96 h (a) and cells were counted (b). c C2C12 myoblasts were differentiated with or without 5 μg/mL IGFBP-3 for 96 h. Differentiated myotubes were indicated as MHC-positive cells. d-f Myotube differentiation rate indicated by percentage of nuclei in MHC-positive cells (d), Myonuclei number per myotube (e), and mRNA expression levels indicated by qPCR of muscle regulatory factor MyoD and Myogenin (f) were measured after differentiation with different doses of IGFBP-3 treatment for 96 h. Data are presented as means ± SEM. * p < 0.05

Back to article page